Dr. Paul Nunzio DeSantis, Pharm.D
Event-driven, research analyst, hedge fund analyst, biotech

pSivida: Positive Roche And Regeneron Conference Calls Confirm Tehadur's Potential

Assessing the Long and Short View of pSivida Corp.

Company Overview

pSivida Corp. (NASDAQ:PSDV) is not a proof-of-concept stage biopharmaceutical company, but is a developer of a proven, sustained release drug delivery system. pSivida already has two approved products, Retisert partnered with Bausch & Lomb for the treatment of chronic noninfectious uveitis, and Iluvien partnered with Alimera Sciences (NASDAQ:ALIM) in the treatment of Diabetic Macular Edema (DME). Iluvien is already approved in 6 EU countries and it is expected to have an FDA decision by 4Q14. pSivida is entitled to 20% royalties of both products and is developing Medidur, which is their first full commercial rights product for posterior Uveitis in Phase III trials. Importantly, pSivida ...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details